NCT02727803 - Personalized NK Cell Therapy in CBT | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 19, 2016

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia With Myelodysplasia-Related ChangesAcute Myeloid Leukemia With Variant MLL TranslocationsB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chemotherapy-Related LeukemiaChronic Myelomonocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsISS Stage II Plasma Cell MyelomaISS Stage III Plasma Cell MyelomaMyelodysplastic SyndromeMyelodysplastic Syndrome With Excess BlastsMyelodysplastic Syndrome With Gene MutationMyelodysplastic/Myeloproliferative NeoplasmPreviously Treated Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Myelodysplastic Syndrome

Interventions

BIOLOGICAL

Allogeneic Natural Killer Cell Line NK-92

Given IV

BIOLOGICAL

Anti-Thymocyte Globulin

Given IV

DRUG

Busulfan

Given IV

DRUG

Clofarabine

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

BIOLOGICAL

Rituximab

Given IV

RADIATION

Total-Body Irradiation

Undergo total body irradiation

PROCEDURE

Umbilical Cord Blood Transplantation

Undergo umbilical cord blood transplantation

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER